Biotech Bros

This week on the podcast Agustin sits down with the Lynn Kirkpatrick the CEO of Ensysce Biosciences. Ensysce is an innovative company that is seeking to address the opioid crisis by leveraging advanced chemistry to prevent opioid abuse and ensure targeted and appropriate dosing of pain medications. Apart from opioids, Ensysce is looking to leverage their technology across a host of indications with the goal of making  drug delivery safer and more effective. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses some new developments in the Alzheimer's space with the FDA's recent CRL for Eli Lilly's beta amyloid antibody. He also shares his thoughts on Leap Therapeutics' acquisition of Flame Biosciences and what it means for future commercialization strategies Dive deep into the motivations and mechanics behind some very successful people.Risk takers, dreamers, business folk and believers discuss the journey toward their goals.Listen on: Apple Podcasts SpotifyIf you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses the excitement for 2023 in biotech investing and highlights some key tailwinds that could provide a return to positive returns for investors. He also discusses the rather lackluster JPM conference and highlights the troubles plaguing Fate Therapeutics and other natural killer cell therapy companies. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.comIf you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin sits down with the Samina Bari. Samina is a biotech executive & strategic advisor, where she drives the development of strategies and compelling corporate narratives that influence investor, media, peer and public perception. On this podcast we discuss a host of topics from Samina's journey, to understanding the importance of value perceptions in biotech, to creating corporate presentations, and identifying red flags early prior to investing in companies.If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses Madrigal Pharmaceuticals' recent phase III win in NASH, he highlights another monoclonal antibody in the Alzheimer's space, and provides a reflection on the markets in 2022. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin shares some recent action and news in the biotech market from failed acquisitions to a pending purchase to questions around a synthetic biology powerhouse.If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin provides updates on key readouts from Affimed and Leap Therapeutics in particular setting the record straight for their recent data readouts. In addition he shares some exciting news regarding a new initiative!If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin talks about the recent fluctuations within the market, the 300 million dollar IPO of a big time base editing gene therapy company, and highlights an interesting play within the NASH space. The Foundation of Daily Health, AG1 by Athletic GreensUnlock Your Free One Year Supply of Vitamin D3+K2 and 5 free Travel Packs If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin sits down with the Bryan Kobel CEO of TC Biopharm. Bryan spent years leading healthcare investment banking at EF Hutton and the Alberleen Group before switching roles and joining TC Biopharm. On this podcast we discuss a host of topics from TC Biopharm's IPO earlier in the year, to the state of biotech and equity markets, to the transformative technology behind TC Biopharm.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin talks recent macroeconomic trends and their implications on the stock market and biotech specifically, highlights the positive phase 3 data for another Biogen Alzheimer's drug, and shares the recent approval for Amylyx Pharmaceuticals and their 6-figure a year drug for ALS. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses news around Amgen's big 1L data drop for its KRAS inhibitor Lumakras, the shifting perceptions for $AMLX and what could become an approval for their ALS therapy, and the shortsightedness of the FDA and CDC around approving covid boosters based only on mouse data!If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin highlights the recent data update from this small biotech company. The company is up already 119% in the past month and their most recent data may convince big pharma that an acquisition is warranted. Additionally, he discusses the one biotech company that the whole street should love: Leap TherapeuticsIf you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin addresses the flurry of acquisitions that have precipitated in the recent weeks as well as the growing excitement in the sector as indices rebound from their May lows. He also highlights the recent data from Alnylam Pharmaceuticals regarding their therapy for ATTR-CM and the increasingly competitive market that is developing.If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses Leap Therapeutics and their R&D day as well as the news that Novartis is discontinuing their PD-L1 submission for NSCLC and finally he sheds light on a scandal that is rocking neuroscience research and Alzheimer's drug development. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses the recent acquisition activity in the biotech space, some positive news for Amylyx Pharmaceuticals regarding a new chance to convince regulators of an approval at their second ad-board, and an incredible data readout for a new gene therapy targeting Huntington's Disease.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses the recent data release from CRISPR Therapeutics, Galapagos' CAR-T cell therapy acquisition, and the over-saturation of SCD therapies entering the market. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin sits down with Maxim Jacobs. Maxim is a senior vice president at Russo Partners and has multiple years of experience in biotech investing. On this episode, Agustin and Maxim discuss the recent biotech market fluctuations and sell-off as well as some practical advice for retail investors looking to enter the space. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

On this week's episode, Agustin discusses the recent data release of Jemperli and how it may be a viable solution for dMMR solid tumor patients. He also provides updates on Amylyx Pharmaceuticals and their recent approval in Canada, Leap Therapeutics and their prostate cancer readout, and Infinity Pharmaceuticals and their risky jam-packed future. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

On this week's episode, Agustin discusses the failures of targeting TIGIT antibodies, the competitive race for KRAS superiority, and the pitfalls of Caribou Biosciences and their allogeneic CAR-T cell therapy. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

On this week's episode, Agustin shares some preliminary insights from ASCO and dives into both the lack of data from $AFMD and the less than spectacular update from $PDSB. Additionally, yet another biotech company has been acquired and this one is a late stage commercial company! Is there hope for $XBI after all?If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin sits down with Jeff Galvin, the CEO and founder of American Gene Technologies, an innovative cell therapy company looking to build the infrastructure necessary to spur innovation in gene and cell therapy development. Much like Microsoft and Apple transformed the tech world, AGT is looking to establish the future of what Jeff calls "TechBio".  To learn more about American Gene Technologies, check them out   https://www.americangene.com/If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin sits down with Rashid Bux, the CEO and founder of BioMark Diagnostics, an early stage innovative diagnostic startup developing a ground breaking metabolomics and biomarker detection platform for oncology.  To learn more about BioMark Diagnostics, check them out  at https://www.biomarkdiagnostics.com/If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

On this week's episode, Agustin highlights the winners and losers of this years AACR conference and discusses how $TGTX went from being a promising biotech investment to a company with limited options and commercial hopes.  If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

On this week's episode, Agustin addresses the unfortunate outcome of the FDA advisory board for Amylyx Pharmaceuticals ($AMLX), elaborates on the importance of AACR for Affimed Pharmaceuticals ($AFMD), and brings to light some serious issues for Moderna ($MRNA) and their pipeline. If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

On this week's episode, Agustin shares his opinion on recent developments within the Covid landscape and the potential for a private vaccine market to emerge. Additionally, he shares his insights on $MEIP's recent misfortune and the FDA's growing reluctance to dole out accelerated approvals for PI3K inhibitors.Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros

On this week's episode, Agustin shares his opinion on recent $XBI fluctuations as well as upcoming data readouts from $AFMD. Additionally, he shares his opinion on whether the recently public Amylyx Pharmaceuticals will be successful in obtaining FDA approval for their therapy targeting ALS.  Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros

 On this week's episode, Agustin discuss the recent updates with Covid manufacturers and where $NVAX stands going forward despite the global equities selloff. Additionally, he shares two key updates regarding CRISPR Manufacturers and how that will impact their long term viability. Finally, make sure to stay tuned for more interviews with key opinion leaders in the healthcare space and a livestream Twitch session to discuss undervalued biotech companies in today's market.  Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros

The world of biotech remains uncertain as the equity markets continue to slide. Despite the sentiment, great buying opportunities remain! On this week's episode, Agustin discuss why purchasing $XBI rarely makes sense in the case of biotech investing and why having a framework can go a long way! Additionally, he discusses some recent updates on high conviction positions and highlights the good news that is coming for $NVAXMake sure to like, comment, subscribe and follow me on Twitter @biotech_bros

As 2022 continues, the sentiment within biotech remains poor. The poor performance of large tech companies like $NFLX and $PTON has caused everything to slide.  On this week's episode, Agustin discusses what the future may look like within biotech and explains why $XBI continues to slide and why $LPTX is still compelling despite questions around safety.Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

Despite the excitement behind JP Morgan's annual healthcare conference, $XBI still has taken a nose dive. On this week's episode, Agustin discuss how to find value among the wreckage that $XBI has generated and highlights in particular one company that he believes may get acquired.

Welcome to 2022! On this episode, Agustin discusses the recent pullback from $XBI and what the future may hold for investors in 2022 and what investments might be worthwhile for this year. With JPM around the corner there are multiple opportunities to add. Additionally, he highlights what the new data release from $CRIS might mean for the company going forward. Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

On this episode, Agustin discusses the recent data presented by $MRNA on their flu asset and how it compares with other manufacturers in the flu market. Additionally, it's yet another stressful time for Novavax investors as the company moves toward an FDA approval. What does the future hold for this Covid vaccine manufacture and will it be successful in achieving commercial and manufacturing success? Tune in to find out!Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin discusses $XBI and what the future holds for biotech investing in 2022. Additionally, he shares his reactions to recent Lancet publications regarding heterologous vaccine usage and comparing different booster shots. Finally, $NVAX has received its first legitimate regulatory approval from the WHO.Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast, Agustin reflects on the biotech sector and the recent price fluctuations in $XBI and highlights while there are several zombie companies that don't have long term potential. Despite these circumstances, $AFMD and $LPTX are exceptions that warrant more capital. Additionally, he reflects on the emergence of a new Covid variant and what that means for manufacturers, investors, and public health officials. Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

As part of the multi-part series on Natural Killer Cell Therapies, this week on the podcast, Agustin discusses $AFMD. He explains the  company's technology, pipeline, and recent catalysts. Additionally, he addresses some key questions including the monotherapy potential of AFM13 and AFM24 and where Affimed stands relative to other companies within the NK cell therapy space.  Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

On this bonus episode Agustin sits down and speaks with Robert Foster, current CEO of Hepion Pharmaceuticals ($HEPA) and previous co-founder of Aurinia Pharmaceuticals ($AUPH) . In this interview, they discuss multiple topics from Robert's previous experience at Aurinia and how he is leveraging those insights to guide drug development at Hepion. They also speak on the NASH landscape and how Hepion is looking to position itself within the market. For access to the video interview make sure to check out my youtube channel later this week!Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros

This week on the podcast Agustin discusses the recent news of oral therapeutics to help treat Covid and what this means going forward for vaccine manufactures. Additionally, he addresses concerns around $NVAX and $GTBP. Finally, he briefly highlights two companies that are looking to present at ASH and what their initial data might suggest going forwardMake sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week's episode is Agustin's conversation with GT Biopharma CEO Anthony "Tony" Cataldo. On this episode they discuss the future of natural killer cell therapies and therapeutics including what makes $GTBP such a compelling company compared to others within this competitive space. Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin discusses the recent data readouts of two allogeneic cell therapy companies. The cell therapy space is heating up and in this episode Agustin addresses some of the pros and cons associated with each of the gene-editing platform technologies currently in developmentMake sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin discusses valuations in the biotech market including the CRISPR companies. Additionally, he shares updates on  past #picksoftheweek and highlights how $NVAX finally has submitted their data for regulatory approval to the WHO.  Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin highlights key readouts from ESMO. In particular he provides context to $LPTX's recent gastric cancer readout and highlights how $CRDF could have a best in class KRAS Colon Cancer Drug. Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin celebrates the acquisition of Trillium Therapeutics, a previous pick of the week, comments on the future acquisition prospects for other CD47 players (i.e. $ALXO/ALX Oncology) within the market, and shares his thoughts on the questionable data behind Cassava Sciences and there dubious efficacy claims. Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin reflects on the current investor sentiment of biotech in the capital markets, the Delta variant and where we stand with vaccine hesitancy, and shares his reaction to Fate Therapeutics ($FATE) and their data as part 1 of the multi-part natural killer cell therapy series.  Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin discusses a perfect example of inefficiency in the biotech markets and why clinical data is all that matters when it comes to evaluating a biotech startup. He also briefly addresses what is up next for $MRNA, $NVAX, and the Delta variant.  Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin discusses the recent pushback on the FDA's decision of Biogen's new Alzheimer's Drug and what that means for the future of neuroscience research and Medicare solvency. He also shares what could be a momentous event for one neuroscience company in particular and finally concludes the episode talking about Covid and what the future holds with the emergence and domination of the Delta variant.  Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin discusses whether we will need booster shots to protect against future variants and provides a comprehensive overview of $CRIS and $KYMR Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin discusses the breakthrough approval by the FDA for Biogen's Aduhelm and what that means for biotech in general and Biogen in particular. He also highlights the ultimate failure that has been CureVac ( $CVAC) in their Covid vaccine development. Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

This week on the podcast Agustin discusses the upcoming readouts from ASCO 2021, highlights the current situation for Covid manufacturers including the over-inflated CureVac ( $CVAC), and celebrates the recent milestone for drug development and the implications on other manufacturers within the KRAS space.Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

After two weeks away we are back with a girthy episode. This week on the podcast Agustin discusses the implications of removing patent protections for the covid vaccines, addresses the numerous delays with $NVAX and shares his thoughts on $TRILMake sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

On this week's episode, Agustin discusses the recent Johnson & Johnson vaccine pause, the failure that is Inovio, and highlights how to navigate volatility within the biotech market!Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

On this week's episode, Agustin highlights the recent readouts at AACR of two companies $ONCT and $AFMD and what those readouts mean for the future!Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros